Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Acacia Research Q1 2026 Earnings Call - Benchmark Drills First Cherokee Well Amid Record Revenue and Hedge Volatility
Acacia Research delivered Q1 2026 revenue of $54.2 million, driven by record energy segment performance and steady manufacturing results, while the IP division remained episodic with minimal licensing...
- Acacia Research reported Q1 2026 revenue of $54.2 million, with operated segment adjusted EBITDA of $6.8 million, excluding IP.
- Benchmark, the energy division, achieved record quarterly revenue of $18.7 million and $7.7 million in adjusted EBITDA, driven by increased production and favorable commodity prices.
- Benchmark successfully drilled and brought online its first Cherokee well in late March, with initial results described as strong and a projected 2.5x multiple on invested capital.
- +7 more takeaways
Avient Corporation Q1 2026 Earnings Call - Pricing Power Offsets Inflation While AI and Packaging Drive Growth
Avient delivered Q1 2026 results that were modestly ahead of expectations, with adjusted EPS of $0.83 and disciplined margin expansion despite a complex operating environment. The company successfully...
- Avient reported Q1 2026 adjusted EPS of $0.83, slightly beating expectations, driven by disciplined cost control and productivity initiatives that offset wage inflation and incentive resets.
- Organic sales were broadly in line with expectations, with packaging, the largest end market, finishing low single-digit growth despite strong prior-year comparisons of 7%.
- Management confirmed it has secured supply for the vast majority of raw materials for Q2, with only select items facing constraints, and expects organic sales growth and margin expansion in the second quarter.
- +9 more takeaways
GoodRx Q1 2026 Earnings Call - Pharma Direct Revenue Surges 82% as Core Business Stabilizes
GoodRx delivered a mixed but strategically decisive first quarter. Revenue hit $194 million, driven by an 82% year-over-year jump in Pharma Direct, which now accounts for nearly a quarter of total sal...
- Pharma Direct revenue grew 82% year-over-year to $52.2 million, becoming the primary growth engine and accounting for nearly 27% of total revenue.
- GoodRx raised full-year 2026 revenue guidance to $765 million to $785 million and adjusted EBITDA guidance to at least $235 million, driven by stronger-than-expected Pharma Direct performance.
- The legacy prescription transaction revenue declined 24% year-over-year to $113.7 million, but monthly active consumers flattened at 5.3 million, signaling an end to the steep sequential declines seen in 2025.
- +7 more takeaways
Tenaris Q1 2026 Earnings Call - Geopolitical Turmoil Tests Supply Chains While North America and Offshore Backlogs Point to Stronger Second Half
Tenaris reported a resilient first quarter with sales rising 6% year-over-year to $3.1 billion and net income jumping 22% to $564 million, despite the sudden closure of the Strait of Hormuz disrupting...
- Sales rose 6% year-over-year to $3.1 billion in Q1 2026, defying Middle East disruptions.
- Net income jumped 22% to $564 million, driven by lower tariff costs and better below-the-line results.
- EBITDA margin held steady at 24%, as higher maintenance costs were offset by tariff savings.
- +7 more takeaways
Celsius Holdings Q1 2026 Earnings Call - Record Revenue Hits $783M as Alani Nu Integration Cuts Costs and Margin Trajectory Holds
Celsius Holdings delivered a record $783 million in first quarter revenue, driven by a 60% surge in Alani Nu sales and steady Celsius performance. The company completed the Alani Nu integration, captu...
- Record first quarter revenue of $783 million, setting a new quarterly high for Celsius Holdings.
- Alani Nu net sales surged 60% year-over-year to $368 million, reflecting strong execution post-acquisition.
- Celsius brand net sales grew approximately 6% year-over-year to $348 million, supported by SKU optimization and Fizz-Free expansion.
- +7 more takeaways
Kulicke and Soffa Q2 2026 Earnings Call - Advanced Packaging Demand Surges as TCB Revenue Exceeds $100M
Kulicke and Soffa delivered a standout second quarter for fiscal 2026, with revenue jumping 21.5% sequentially to nearly $275 million, driven by a sharp rebound in memory shipments and robust demand f...
- Revenue surged 21.5% sequentially in Q2 FY2026, driven by a 93% jump in memory shipments and strong general semiconductor demand.
- Thermal compression bonding (TCB) revenue is on track to exceed $100 million for the full fiscal year, growing at least 70% sequentially.
- Management announced plans to expand Advanced Solutions production capacity to support approximately $400 million in annual revenue, with $12 million in capital expenditures allocated in FY2026.
- +7 more takeaways
Somnigroup International Q1 2026 Earnings Call - EBITDA Margins Expand as Mattress Firm Synergies Drive Profitability
Somnigroup International delivered a resilient first quarter in 2026, with net sales rising 12% to $1.8 billion and adjusted EBITDA jumping 20% to $297 million. The results underscore the operating le...
- Net sales grew 12% to $1.8 billion, with adjusted EBITDA rising 20% to $297 million, driven by strong operating leverage and cost discipline.
- Adjusted EPS increased 20% to $0.59 per share, reflecting a 100+ basis point expansion in EBITDA margins despite a challenging macro environment.
- Global bedding demand declined mid-single digits in Q1, but Somnigroup outperformed the market across all major segments, including North America, International, and Mattress Firm.
- +12 more takeaways
1-800-FLOWERS.COM, Inc. Q3 FY2026 Earnings Call - Cost Savings Ahead of Plan, Marketing Pivot Begins
1-800-FLOWERS.COM is stabilizing. Revenue fell 11.6% in Q3 FY2026, dragged by an 18.7% plunge in Consumer Floral & Gifts, but the company hit its $50 million cost savings target a year early. Manageme...
- Revenue declined 11.6% year-over-year, with Consumer Floral & Gifts down 18.7% and Gourmet Foods & Gift Baskets essentially flat.
- Company achieved its $50 million annualized cost savings target ahead of schedule, with an additional $15-20 million in savings targeted for the next fiscal year.
- Management is pivoting marketing strategy from bottom-funnel transactional spending to top and mid-funnel brand building, including influencer marketing on TikTok and Instagram.
- +7 more takeaways
Ispire Technology Q3 2026 Earnings Call - Cash Flow Inflection Point and Malaysia Manufacturing Advantage
Ispire Technology reported a revenue dip to $18.7 million for fiscal Q3 2026, but management framed the quarter as a decisive turning point in the company’s restructuring. Sequential cash grew by $468...
- Revenue declined to $18.7 million in fiscal Q3 2026, down from $26.2 million year-over-year, though the sequential drop was only 8%, marking the most resilient second-to-third quarter performance in company history.
- Sequential cash growth of $468,000 brought the cash balance to $18 million, reinforcing management’s confidence in reaching cash flow positivity in the second half of calendar 2026.
- Gross margin stood at 10.7%, with gross profit negatively impacted by $2.2 million in one-time product returns from a legacy cannabis customer no longer in the supply chain.
- +7 more takeaways
Collegium Pharmaceutical Q1 2026 Earnings Call - AZSTARYS Acquisition Accelerates ADHD Growth
Collegium Pharmaceutical reported a strong start to 2026, driven by a 36% year-over-year surge in Jornay PM net revenue to $38.9 million and a durable 4% growth in its pain portfolio. The company succ...
- Jornay PM net revenue surged 36% year-over-year to $38.9 million, driven by a 14% increase in prescriptions and a 17% expansion in the prescriber base to an all-time high of 30,000.
- The company announced a $650 million cash acquisition of AZSTARYS, a differentiated ADHD treatment, which is expected to close in the second quarter of 2026 after the Hart-Scott-Rodino waiting period expired.
- Total pain portfolio net revenues grew 4% year-over-year to $154.6 million, with BELBUCA up 2% and XTAMPZA ER up 7%, providing a stable cash flow foundation for the business.
- +9 more takeaways